论文部分内容阅读
目的:观察微调五号方(WD-5)或WD-5联合生物反应调节剂(IL-2和IFN-α2b)对Ⅲ、Ⅳ期肾癌患者生存质量的影响。方法:Ⅲ、Ⅳ期肾癌患者共40例,按随机数字表法分为治疗组(WD-5+生物反应调节剂)及对照组(单纯生物反应调节剂),治疗2个疗程后观察两组患者治疗前后实体瘤大小、临床常见症状改善情况、Karnofsky体力状况评分、细胞免疫功能水平、肿瘤标志物水平、生命质量评分,以及治疗毒副反应。结果:WD-5+生物反应调节剂在缓解临床症状、提高卡氏评分、提高细胞免疫功能、降低肿瘤标志物水平、提高患者生命质量、减轻生物反应调节剂治疗的毒副反应方面优于单纯使用生物反应调节剂。结论:WD-5联合IL-2和IFN-α2b治疗Ⅲ、Ⅳ期肾细胞癌,能够缓解患者临床症状和体征,提高患者细胞免疫功能,改善体力状况,提高生命质量,且治疗毒副反应减轻。
OBJECTIVE: To observe the effect of fine-tuning WD-5 or WD-5 combined with biological response modifiers (IL-2 and IFN-α2b) on the quality of life of patients with stage Ⅲ and Ⅳ renal cell carcinoma. Methods: A total of 40 patients with stage III and IV renal cell carcinoma were divided into treatment group (WD-5 + biological response modifier) and control group (simple biological response modifier) according to random number table. After two courses of treatment, The size of the solid tumor before and after treatment, the improvement of clinical symptoms, Karnofsky physical status score, cellular immune function level, tumor marker level, quality of life score, and treatment side effects. Results: WD-5 + biologic response modifier was superior to simplex in alleviating clinical symptoms, improving Karnaugh’s score, improving cellular immune function, reducing tumor marker level, improving patient’s quality of life and alleviating toxicity of biological response modifier Use biological response modifiers. Conclusions: WD-5 combined with IL-2 and IFN-α2b can treat stage Ⅲ and Ⅳ renal cell carcinoma, which can alleviate clinical symptoms and signs, improve cellular immune function, improve physical condition, improve quality of life and reduce the side effects of treatment .